 |
|
|
|
 |
|
|
| Article 1 to 6 out of 6 concerning DAIICHI SANKYO COMPANY, LIMITED
|
-
Ranbaxy to Bring in Daiichi Sankyo as Majority Partner
(06/13/2008)
Daiichi Sankyo Company, Limited and Ranbaxy Laboratories Limited announced that a binding Share Purchase and Share Subscription Agreement (the "SPSSA") was entered into between Daiichi Sankyo, Ranbaxy and the Singh family, the largest and ...
-
DAIICHI SANKYO Extends Alliance with MorphoSys for Use of HuCAL GOLD to Develop Novel Antibody Therapies
(03/27/2008)
MorphoSys AG announced that DAIICHI SANKYO COMPANY, LIMITED has triggered its pre-existing option to extend the current collaboration between the two companies. The collaboration, originally signed in March 2006, was to end in March 2008. Under the ...
-
Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
(11/06/2007)
Duke Clinical Research Institute to lead multinational study with investigational compound
A large Phase III clinical trial is anticipated to begin in the second quarter of 2008 to compare the effects of prasugrel, an investigational oral antiplatelet agent, against clopidogrel (Plavix(R)/Iscover(R)) in medically managed patients with ...
-
LANI completes Phase I in Japan and to commence Phase I in UK
(04/27/2007)
Biota Holdings Limited announced that its long acting neuraminidase inhibitor (LANI), CS8958, an anti-influenza treatment, has demonstrated effectiveness against the avian flu virus H5N1, completed Phase I studies in Japan and received ethics ...
-
YM Biosciences Licenses Monoclonal Antibody, Nimotuzumab, to Daiichi Pharmaceutical for Japan
(08/02/2006)
YM BioSciences Inc. announced that its majority owned subsidiary, CIMYM BioSciences Inc., has licensed development and marketing rights in Japan for its anti-EGFR humanized antibody, nimotuzumab, to Daiichi Pharmaceutical Co., Ltd. (a wholly owned ...
-
Exelixis and Sankyo Sign Collaboration Agreement to Develop Novel Therapies for Cardiovascular Disease
(03/22/2006)
Exelixis, Inc. and Sankyo Company (a wholly owned subsidiary of DAIICHI SANKYO COMPANY, LIMITED) announced a collaboration agreement to discover, develop and commercialize novel therapies targeted against the mineralocorticoid receptor (MR), a ...
|
|
|
|
|
Top